Anzeige
Mehr »
Login
Freitag, 03.12.2021 Börsentäglich über 12.000 News von 683 internationalen Medien
Hot Stock! Aktie des Tages: Letzte Einstiegchance vor Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A114PL ISIN: GB00BMJ6DW54 Ticker-Symbol: IEA 
Stuttgart
03.12.21
08:02 Uhr
5,240 Euro
-0,104
-1,95 %
Branche
Medien
Aktienmarkt
FTSE-100
1-Jahres-Chart
INFORMA PLC Chart 1 Jahr
5-Tage-Chart
INFORMA PLC 5-Tage-Chart
RealtimeGeldBriefZeit
5,3565,53411:41
GlobeNewswire (Europe)
355 Leser
Artikel bewerten:
(2)

Informa Business Intelligence: Citeline Connect Clinical Trial Recruitment Platform Announces Expansion of Reach into all Global Markets

Platform's recruitment capabilities have grown to support over 30 countries globally

NEW YORK, Oct. 20, 2021, the all-in-one clinical trial recruitment platform developed by Informa Pharma Intelligence, is expanding its technology and referral network to include EU and global markets.

The expansion comes on the heels of Citeline Connect's success in recruiting for Moderna's Phase III COVID-19 vaccine trial, particularly for diverse participants. Diane Montross, Senior Director of Patient Recruitment & Retention at Moderna, spoke on the speed and success of the COVE Study recruitment efforts in a presentationat the recent DPharm conference.

In addition, as the following statistics from Trialtrove indicate, over half of all registered clinical trials involving a drug intervention are conducted outside the US:

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6b9e1c84-9cfa-4405-bc7a-545af1e9f918

LocationNumber of trials
% of total
US only88,305 24%
Non-US only257,948 69%
US and non-US10,506 3%
Unknown14,414 4%
Total371,173 100%

"Based on our overwhelming success recruiting for US-based trial sites, combined with the increased need for trial participants at sites outside the US, we saw an opportunity for Citeline Connect to help more study sponsors meet enrollment goals," said Chris Venezia, Chief Commercial Officer at Citeline Connect. "Our robust prescreening process minimizes screen fails, enabling sponsors to recruit faster and more efficiently than ever before."

Citeline Connect has already begun recruiting trial participants globally, and with new consent and platform enhancements the recruitment capabilities have grown to support over 30 countries globally, including the UK, Canada, Austria, Italy, France, Ireland, Germany, Spain, Poland, Hungary, New Zealand, Denmark, Belgium, Portugal, Bulgaria, Israel, Turkey, Taiwan, Australia, Japan, Brazil, Korea, Switzerland, Singapore, Argentina, Georgia, Colombia, Malaysia, India and Russia.

For more information, visit Citeline Connector contact?pharma@informa.com.

About Informa Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products - Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Biomedtracker, Scrip, Pink Sheet and In Vivo - to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

With more than 400 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn't covered through the breadth and depth of data available to customers. For more information, visit pharmaintelligence.informa.com.

Informa Pharma Intelligence PR Contact
Diffusion PR for Informa Pharma Intelligence
informapharma@diffusionpr.com
(213) 318-4500


INFORMA-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2021 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.